Hyperion DeFi (NASDAQ:HYPD) Downgraded to Strong Sell Rating by Zacks Research

Zacks Research lowered shares of Hyperion DeFi (NASDAQ:HYPD) from a hold rating to a strong sell rating in a research report sent to investors on Wednesday,Zacks.com reports.

Several other brokerages have also recently commented on HYPD. Chardan Capital reiterated a “buy” rating and issued a $7.30 target price on shares of Hyperion DeFi in a report on Tuesday. Weiss Ratings upgraded shares of Hyperion DeFi from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, June 24th. Finally, Cantor Fitzgerald raised their price objective on shares of Hyperion DeFi from $6.60 to $7.10 and gave the stock an “overweight” rating in a research note on Thursday. Two investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $7.20.

Hyperion DeFi Trading Up 5.2%

Shares of NASDAQ HYPD opened at $2.83 on Wednesday. The company has a quick ratio of 1.97, a current ratio of 1.97 and a debt-to-equity ratio of 0.12. Hyperion DeFi has a 12 month low of $2.34 and a 12 month high of $15.00. The company has a market cap of $42.90 million, a price-to-earnings ratio of -0.43 and a beta of 2.53. The business has a fifty day simple moving average of $2.91 and a 200-day simple moving average of $3.36.

Hyperion DeFi (NASDAQ:HYPD) last issued its quarterly earnings results on Thursday, August 13th. The company reported $0.92 earnings per share for the quarter. The firm had revenue of $0.36 million for the quarter. Hyperion DeFi had a negative return on equity of 13.93% and a net margin of 416.56%. Sell-side analysts predict that Hyperion DeFi will post 1.69 EPS for the current year.

Insider Activity at Hyperion DeFi

In related news, insider Hyunsu Jung purchased 7,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was acquired at an average cost of $3.70 per share, for a total transaction of $25,900.00. Following the completion of the acquisition, the insider owned 1,384,676 shares in the company, valued at $5,123,301.20. This trade represents a 0.51% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 7.50% of the company’s stock.

Institutional Investors Weigh In On Hyperion DeFi

A number of institutional investors have recently modified their holdings of the stock. Redwood Wealth Management Group LLC grew its holdings in shares of Hyperion DeFi by 2.1% during the 1st quarter. Redwood Wealth Management Group LLC now owns 183,273 shares of the company’s stock valued at $632,000 after acquiring an additional 3,690 shares in the last quarter. Sanctuary Advisors LLC purchased a new stake in shares of Hyperion DeFi during the fourth quarter worth $38,000. Nations Financial Group Inc. IA ADV purchased a new stake in shares of Hyperion DeFi during the fourth quarter worth $40,000. Price T Rowe Associates Inc. MD acquired a new stake in Hyperion DeFi during the fourth quarter valued at $73,000. Finally, State Street Corp acquired a new stake in Hyperion DeFi during the fourth quarter valued at $92,000. Institutional investors and hedge funds own 25.84% of the company’s stock.

About Hyperion DeFi

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.